National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 679089

Case Details

VAERS ID: 679089 (history)  
Age:   
Gender: Female  
Location: Foreign  
Vaccinated:0000-00-00
Onset:0000-00-00
Submitted: 2017-01-23
Entered: 2017-01-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV4: HPV (GARDASIL) / MERCK & CO. INC. - / 2 UN / UN

Administered by: Other       Purchased by: Unknown
Symptoms: Adverse reaction, Fatigue, Food allergy, Mental disorder, Migraine, Muscular weakness, Physical disability, Respiratory distress, Social avoidant behaviour, Visual impairment
SMQs:, Rhabdomyolysis/myopathy (broad), Anaphylactic reaction (broad), Peripheral neuropathy (broad), Anticholinergic syndrome (broad), Dementia (broad), Acute central respiratory depression (broad), Psychosis and psychotic disorders (broad), Guillain-Barre syndrome (broad), Noninfectious encephalopathy/delirium (broad), Glaucoma (broad), Optic nerve disorders (broad), Lens disorders (broad), Retinal disorders (broad), Hypersensitivity (broad), Respiratory failure (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Hypoglycaemia (broad)

Life Threatening? No
Died? No
Permanent Disability? Yes
Recovered? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Parity 2
Diagnostic Lab Data:
CDC Split Type: DK0095075131612DNK004576

Write-up: This literature marketed report was received from the authors of a published literature article, titled as stated above, concerning a 40 year old female patient, enrolled in a retrospective study aimed to examine their experiences of side effects from the human papillomavirus (HPV) vaccine. The patient had two children and was a full time graphical designer. Her status before vaccination was reported as healthy. On an unknown date, the patient received her first and second dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (manufacturer unknown) (dose and route of administration were not reported). On an unknown date in 2013, the patient received the third dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (manufacturer unknown) (dose and route of administration were not reported). On an unknown date, after the first dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine(manufacturer unknown), the patient experienced side effects, which aggravated after the next dose of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (manufacturer unknown). The patient felt exceedingly physically and mentally confined in her everyday life, which led her to live a more restricted and solitary life. All the women link their symptoms to quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (manufacturer unknown) because they occurred soon after vaccination. Generally, the women tend not to perceive themselves as ill, but rather as more physically and mentally constrained than they were before having their vaccination. The lack of acceptance from family and friends has led the women to distance themselves from others and lead a more socially isolated life. The outcome of the event of side effects was not reported. Follow up information was received from the author of the literature article entitled as stated above on 17-JAN-2017.On an unknown dates (also reported as "2013"), the patient was vaccinated with dose 1 and dose 2 of GARDASIL (site, route and lots numbers not reported). In 2013 the patient was vaccinated with dose 3 of SILGARD (site, route and lot number not reported). In 2013 the patient experienced muscular weakness in the legs, respiratory distress, food allergies, migraine, visual disturbance and fatigue. The patient was treated with migraine tablets and asthma medication. The outcome of muscular weakness, fatigue, visual impairment, migraine, food allergy and respiratory distress was unknown. The reporter considered muscular weakness in the legs, respiratory distress, food allergies, migraine, visual disturbance and fatigue serious as disability. Upon internal review respiratory distress was also considered serious as medically significant. The reporter considered that muscular weakness in the legs, respiratory distress, food allergies, migraine, visual disturbance and fatigue were not related to GARDASIL nor SILGARD. This is one of several reports received from the same literature article (cross referenced with MARRS #1612DNK004981, #1612DNK004850, #1612DNK004996, #1612DNK004841, #1612DNK004650, #1612DNK004656, #1612DNK004588). Additional information is not expected as the author does not have any additional information.; Sender''s Comments: DK-009507513-1612DNK004981: DK-009507513-1612DNK004850: DK-009507513-1612DNK004996: DK-009507513-1612DNK004841: DK-009507513-1612DNK004650: DK-009507513-1612DNK004656: DK-009507513-1612DNK004588:


New Search

Link To This Search Result:

http://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=679089


Copyright © 2017 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166